Licensing Agreement

Oxford Biomedica PLC
06 June 2005


FOR IMMEDIATE RELEASE                                               6 JUNE 2005

     OXFORD BIOMEDICA SIGNS LENTIVECTOR(R) LICENSING AGREEMENT WITH PFIZER

Oxford, UK: 6 June 2005 - Oxford BioMedica (LSE: OXB), the leading gene therapy
company, announced today that it has signed a licence agreement for its
LentiVector technology with Pfizer (NYSE: PFE). The agreement provides Pfizer
with use of the Company's proprietary LentiVector gene delivery system for
research activities. Under the terms of the agreement, Oxford BioMedica will
receive an upfront licence payment and an annual maintenance fee. Further
financial details were not disclosed.

Oxford BioMedica's lentivirus-based gene delivery technology, known as
LentiVector, is one of the most powerful technologies for the delivery of genes
to a wide range of cell and tissue types. The LentiVector technology has
applications both in therapeutic products and as a drug discovery tool for
target validation and the creation of targeted disease models. It has also been
shown to enhance the efficiency of making transgenic birds and mammals. Oxford
BioMedica has a comprehensive portfolio of US and European patents that cover
the LentiVector technology.

Commenting on the news Oxford BioMedica's Senior Vice President Commercial
Development, Peter Nolan, said: 'We are delighted to add Pfizer to our list of
licensees for the LentiVector technology The versatility and safety of
lentiviral vectors make them the system of choice for gene target validation in
the drug discovery process as well as for the direct therapeutic applications in
neurotherapy that Oxford BioMedica is pursuing. An increasing number of
companies are using the LentiVector technology and we expect to establish a
number of new partnerships around the technology'.

                                     -Ends-


For further information, please contact:
Oxford BioMedica plc:                                  Tel: [phone]
Professor Alan Kingsman, Chief Executive
Peter Nolan, SVP Commercial Development

City/Financial Enquiries:
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson
Buchanan Communications                                Tel: [phone]

Scientific/Trade Press Enquiries:
Sue Charles/ Katja Stout/ Ashley Lilly
Northbank Communications                               Tel: [phone]



Notes to editors

1. Oxford BioMedica
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on the areas of
oncology and neurotherapy. The Company was established in 1995 as a spin out
from Oxford University, and is listed on the London Stock Exchange.

Oxford BioMedica has core expertise in gene delivery, as well as in-house
clinical, regulatory and manufacturing know-how. In oncology, the pipeline
includes an immunotherapy and a gene therapy in multiple Phase II trials, and a
preclinical targeted antibody therapy in collaboration with Wyeth. In
neurotherapy, the Company's lead product is a gene therapy for Parkinson's
disease, which is expected to enter clinical trials in early 2006, and four
further preclinical candidates. The Company is underpinned by over 80 patent
families, which represent one of the broadest patent estates in the field.

The Company has a staff of approximately 65 split between its main facilities in
Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.
Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Amersham,
Viragen, MolMed and Kiadis; and has licensed technology to a number of companies
including Merck & Co and Biogen Idec.
Further information is available at http://www.oxfordbiomedica.co.uk

2. LentiVector technology
Oxford BioMedica's LentiVector gene delivery technology, based on lentiviruses,
is arguably the most potent system currently available for treating a range of
diseases, particularly those of the central nervous system. Oxford BioMedica has
shown that its lentiviral vectors are able to deliver genes with high efficiency
to a variety of both dividing and non-dividing cells, including neurons in the
brain.

Oxford BioMedica has three issued US patents and a European patent for its
LentiVector technology. These include broad composition of matter claims and
methods of production claims for lentiviral vector gene delivery systems of both
human and non-human origin. The patents also cover derivatives of lentiviral
vector systems that, unlike many versions of lentiviral vectors, have real
clinical utility because of their safety.

The Company has established a neurotherapy pipeline of product candidates based
on its LentiVector technology, which includes ProSavin(R) for Parkinson's
disease, RetinoStat(R) for retinopathy, MoNudin(R) for motor neuron disease,
SMN1-G for spinal muscular atrophy and Innurex(R) for nerve repair. Current
licensees of the LentiVector technology include Merck & Co and Biogen Idec.

3. Pfizer
Pfizer Inc (NYSE: PFE) discovers, develops, manufactures, and markets leading
prescription medicines for humans and animals and many of the world's best-known
consumer brands. Pfizer's innovative, value-added products improve the quality
of life of people around the world and help them enjoy longer, healthier, and
more productive lives. The company has three business segments: health care,
animal health and consumer health care. Pfizer's products are available in more
than 150 countries.



                      This information is provided by RNS
            The company news service from the London Stock Exchange